• Lexaria’s patented DehydraTECH(TM) technology has proven, in the NIC-A21-1 animal study, to be 10-20 times faster in reaching peak delivery of nicotine to the bloodstream than controls
• The company hopes to affirm this in the NIC-H22-1 human nicotine study as their DehydraTECH-nicotine pouch performance will be compared to existing leading brands currently sold in the United States such as ON! and Zyn
• Lexaria has separately announced new agreements with Altria that will see the company receive a fee to provide certain DehydraTECH powder-based nicotine formulations that Altria will evaluate
• The company hopes that this, coupled with the human clinical study, will confirm that purified nicotine with DehydraTECH leads to better oral tissue absorption and reduced negative experiences relative to existing brands

Lexaria Bioscience (NASDAQ: LEXX) has made a name for itself as a global innovator in drug delivery platforms. Its patented DehydraTECH(TM) technology, promotes fast-acting, less expensive, and more effective oral drug delivery, proven through in vivo, in vitro, and human clinical testing.

So far, Lexaria has filed for patent protection for specific delivery of vitamins, NSAIDs, estrogen, cannabinoids, testosterone, PDE5 inhibitors, and terpenes, among others. However, one product that…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.